Navigation Links
Boston Scientific Announces Favorable Ruling in Patent Infringement Case
Date:1/23/2012

NATICK, Mass., Jan. 23, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces that the U.S. District Court for the District of New Jersey has found all the asserted patents in a suit brought by Johnson & Johnson to be invalid and entered judgment in favor of Boston Scientific.

As part of a 2008 suit, Johnson & Johnson alleged that Boston Scientific's PROMUS® Everolimus-Eluting Coronary Stent System infringed two patents, U.S. Patent Nos. 5,516,781 and 5,563,146 (known as "the Morris patents").  The patents relate to the use of a drug on a drug-eluting stent.

"We are pleased with the Court's finding that both of these Johnson & Johnson patents are invalid," said Tim Pratt, Executive Vice President, Chief Administrative Officer and General Counsel for Boston Scientific.  "Boston Scientific will continue to vigorously defend against any claims of infringement."

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding litigation outcome and our product, litigation and risk management strategies.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial
2. nContacts Cardiac Ablation Technology to be Presented in Two Noteworthy Posters at Boston Atrial Fibrillation Symposium 2012
3. Boston Scientific Raises Awareness of Heart Disease at Brandon Jennings Invitational
4. Boston Scientifics Alair® Bronchial Thermoplasty System Achieves Important Reimbursement Milestones
5. Boston Scientific to Participate in 30th Annual J.P. Morgan Healthcare Conference
6. Boston Scientific Launches Charger™ PTA Balloon Catheter
7. Boston Scientific Receives FDA Approval for New Infinion™ 16 Percutaneous Lead for Precision Plus™ Spinal Cord Stimulator System
8. Boston Scientific Introduces Industry-Leading ICD and CRT-D Device Warranties
9. Boston Scientifics WATCHMAN® Device Implanted in First Patients in Latin America
10. Boston Scientific Applauds Introduction of Patient Access to Medical Innovation Act
11. Boston Scientific SYNERGY™ Stent Demonstrates Comparable Safety and Effectiveness Outcomes Versus PROMUS Element™ Platinum Chromium Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017  PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical ... diseases in children, today reported financial results for ... 31, 2016 and provided an update on its ... make progress during the fourth quarter of 2016 ... primate safety study, and with our lead development ...
(Date:3/24/2017)... , March 24, 2017 Abdominal Aortic Aneurysm Repair Devices ... by 2022, Globally, registering a CAGR of 5.1% from 2016 to 2022. The endovascular ... to dominate the market during the study period. Continue ... ... ...
(Date:3/24/2017)... , Mar. 24, 2017 Research ... Management in the U.S.: Consumer Strategies" report to their ... ... how adults approach and treat their physical pain, emphasizing consumer ... distinct groups: pain sufferers and adults who have selected illnesses/conditions ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... contaminated soil, dredged material, and hazardous and non-hazardous materials announced today the acquisition ... This acquisition will add four additional processing facilities and a vast array ...
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management Association ... The annual awards, now in their 12th year, are among the most prestigious in ... In 2016, the awards were retooled to recognize achievements in both large budget (over ...
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic healer and teacher ... Healing and Spiritual Awakening, proudly presents her Sacred Peru retreat with world ... and spiritual journey during the Summer Solstice will also be her final international ...
(Date:3/24/2017)... ... ... The law firm of Enea, Scanlan & Sirignano, LLP, with ... C. Enea has joined the firm as an associate attorney. Ms. Enea, who previously ... law, Medicaid planning and applications, and Wills, Trusts and Estates. Samantha A. Lyons, ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding ... God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true communion with ... Walk with God #TruthwithGrace” is the creation of published author Lea Michelle Johnson, ...
Breaking Medicine News(10 mins):